Porsolt

Porsolt is a long established preclinical CRO, having started operations in 1984 under the name ITEM-Labo. Porsolt has obtained an international reputation for expertise in physiopathological models, customized procedures and tailored solutions for discovering treatments of psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, and metabolic and eating disorders. Porsolt also offers services for safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration in full compliance with GLP (ICH S7), including full assessment of arrhythmogenic risk and abuse and dependence liability. Porsolt is headquartered in France with facilities in Paris and Laval. In 2010 Porsolt opened a subsidiary in Texas (US) to carry out studies in primates, specifically for assessing abuse/dependence liability, and extending this to cognition (Alzheimer’s), pain, electroencephalogram (EEG), and cardiovascular and respiratory.